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Abstract
Background: XCiDaBLE is a large, prospective, observational ‘‘naturalistic’’ study evaluating XeominH for Cervical Dystonia or BLEpharospasm in the United
States. We report the interim results from the blepharospasm cohort of XCiDaBLE.
Methods: Subjects (§18 years old) with blepharospasm were followed for two treatment cycles of incobotulinumtoxinA and monitored for 4 weeks after injection
via interactive voice/web response system (IVRS/IWRS). The investigator-reported scale includes the Clinical Global Impression Scale-Severity subscale (CGI-S).
Patient-reported outcome measures include the Patient Global Impression Scale-Severity (PGI-S) and -Improvement (PGI-I) subscales, Jankovic Rating Scale (JRS),
SF-12v2H health survey, and Work Productivity and Activity Impairment questionnaire. Subjects are seen by the investigator at baseline (including the first
injection), during the second injection, and at a final study visit (12 weeks after the second injection).
Results: One hundred seventy subjects were included in this interim analysis. The majority of subjects were female (77.1%) and white (91.8%), and had previously
been treated with botulinum toxins (96.5%). The mean total dose (both eyes) was 71.5 U of incobotulinumtoxinA for the first injection. PGI-S, PGI-I, and JRS
scores were significantly improved 4 weeks after treatment (all p,0.0001). No differences were noted in either quality of life (QoL) or work productivity in this short
assessment period. No unexpected adverse events occurred.
Discussion: This is an interim study and assessment method based on an IVRS/IWRS. In this predominantly toxin-experienced cohort, significant benefits in
specific and global measures of disease severity were seen in the immediate post-incobotulinumtoxinA injection period. It will be interesting to see if there are
improvements in QoL with consistent individualized injections over a longer period.
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Introduction
Blepharospasm is a focal dystonia characterized by involuntary eyelid
closure, usually bilaterally, with contractions of the orbicularis oculi
muscles and other facial muscles.1 The prevalence of blepharospasm in
the general population is estimated at approximately five in 100,000 in
the USA.2 Because of the frequent blinking and spasmodic closure of the
eyelids, subjects’ daily activities, such as driving, walking, or reading, can
be severely impaired.3 Blepharospasm can also negatively affect the
subject’s employment status and social interactions.3 In 2008, the
Therapeutics and Technology Assessment Subcommittee of the
American Academy of Neurology recommended, based on two class
II studies, Level B, botulinum toxin treatment as an ‘‘option’’ for
patients with blepharospasm.4 Accumulating evidence has now reported
the efficacy and safety of botulinum toxin for treatment of blephar-
ospasm.5–8
Clostridium botulinum produces eight distinct toxin serotypes, but only
two, types A and B, are commercially available for clinical use in the
USA.9 Two type A botulinum toxins, incobotulinumtoxinA (XeominH,
NT201) and onabotulinumtoxinA (BotoxH), are approved by the Food
and Drug Administration (FDA) for use in subjects with blephar-
ospasm. IncobotulinumtoxinA is a botulinum neurotoxin formulation
free from complexing proteins and received FDA approval on July 30,
2010, for the treatment of cervical dystonia (CD) and blepharospasm
in adults.10 IncobotulinumtoxinA has demonstrated efficacy and safety
in the treatment of subjects with blepharospasm in two Phase III
and one Phase IV clinical trials.5–8,11 In head-to-head trials,
incobotulinumtoxinA demonstrated comparable efficacy and safety
to onabotulinumtoxinA.6,11
The ongoing XeominH for Cervical Dystonia or BLEpharospasm
(XCiDaBLE) is the latest and largest multicenter, prospective,
observational Phase IV clinical study in subjects treated with
incobotulinumtoxinA for CD or blepharospasm (Trial Registration:
NCT01287247, www.clinicaltrials.gov). The inclusion and exclusion
criteria applied to subjects enrolled were broad. In XCiDaBLE,
investigators used less selective and a wider range of subjects with
blepharospasm; they included subjects they believed would benefit from
incobotulinumtoxinA treatment. The aims of the study were to mimic
‘‘real-world’’ clinical practice, and capture clinical use and outcome data
of subjects treated with incobotulinumtoxinA for CD or blepharospasm.
XCiDaBLE is ongoing and here we report findings from the first
170 subjects with blepharospasm enrolled in the clinical trial, including
baseline demographic, clinical characteristics and results from the
initial 4 weeks after first injection. The findings from the first 145
subjects with CD enrolled in XCiDaBLE, including baseline
demographic and clinical characteristics and results from the initial
12 weeks after injections, have been published previously.12
Methods
Subjects
To be included, subjects had to be 18 years old or older, could not
have been enrolled in a clinical trial within the past 3 months, and did
not have any contraindications according to the US Prescribing
Information for incobotulinumtoxinA. All subjects signed a written
informed consent prior to inclusion in the study.
Randomization
XCiDaBLE was a prospective, observational study and no
randomization was performed.
Study drug and injection technique
Subjects underwent two injection sessions of incobotulinumtoxinA
in the study. The dose for both injections, the timing of the second
injection, the dilution with normal saline, the muscles to be injected
with incobotulinumtoxinA, and the choice of guidance techniques used
in this trial were at the discretion of the treating investigator. The
second injection was to occur at least 6 weeks after the first injection.
In this study, incobotulinumtoxinA was administered in the orbicularis
oculi, procerus, and corrugator supercilii muscles.
Study visits
Subjects were assessed at the baseline visit and if they met eligibility
criteria received an injection of incobotulinumtoxinA. Information
regarding the injection was collected and included: number of muscles
injected, dose per muscle, and dilution of incobotulinumtoxinA.
Previous use and outcomes of prior botulinum toxin treatment and
other local or surgical treatments were collected. Demographic
information, disease and employment history were collected.
Subjects were asked to rate the efficacy of their previous botulinum
toxin treatment(s) (i.e., none, partial, positive, unknown). According to,
and dependent on, clinical practice, subjects were seen by the
investigator at three visits, which included a baseline visit (including
the first injection), a second injection visit, and a final study visit (12
weeks after the second injection).
Investigator-reported outcome measures
Clinical global impression scale-severity subscale. The Clinical Global
Impression Scale-Severity subscale (CGI-S) was completed by the
treating investigator at each injection. The CGI-S measures the overall
illness severity using a one-item, 7-point Likert scale (where 15normal,
25borderline, 35mildly, 45moderately, 55markedly, 65severely,
75extremely).
Patient-reported outcome measures
Subjects used an interactive voice/web response system (IVRS/
IWRS) throughout the trial to report assessments.
Efficacy
Patient global impression scale-severity (PGI-S) and -improvement
(PGI-I) subscales. The PGI-S was completed at each injection visit and
the PGI-I was completed 4 weeks post injection and at the trial
endpoint. The PGI-S measures the overall illness severity using a one-
item, 7-point Likert scale (where 15normal, 25borderline, 35mildly,
45moderately, 55markedly, 65severely, 75extremely). The PGI-I
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measures global improvement for the area being treated using a one-
item, 7-point Likert scale (where 15very much improved, 25much
improved, 35minimally improved, 45no improvement, 55minimally
worse, 65much worse, 75very much worse).
Jankovic rating scale. The Jankovic Rating Scale (JRS) was assessed at
each injection visit, 4 weeks after injection, and at the trial endpoint by
the subject. The JRS is a validated, disease-specific scale used to rate
the severity and frequency of blepharospasm on a scale of 0 to 4 points
(where severity: 05none, 15minimal, 25mild, 35moderate,
45severe; frequency: 05none, 15slightly increased, 25eyelid flutter-
ing, 35eyelid spasm, 45functionally ‘‘blind’’). The overall score (JRS
Sumscore) is the sum of the scores from these two subscales (maximum
8 points).13
Quality of life. Quality of life (QoL) was assessed using the SF-12v2,
which was completed by the subject at each injection and at the end of
the trial. SF-12v2 is a shorter version of the Medical Outcomes Study
Short-Form (36-item) Health Survey (SF-36H) composed of 12
questions to measure functional health and well-being from the
subject’s point of view.14 The SF12v2 score ranges from 0 to 100, with
higher scores representing better QoL in both mental and physical
components.
Work history. Work history was assessed using the validated Work
Productivity and Activity Impairment (WPAI) questionnaire. The
WPAI questionnaire consists of six questions and is a patient-reported
quantitative assessment of the level of absenteeism, presenteeism, and
daily activity impairment attributable to general health or a specific
health problem.15 Each question is evaluated individually and there is
no total score. Subjects rated their health affecting non-work activities
on a scale of 0 to 10 (where 05no effect to 105significant effect). The
WPAI questionnaire was completed by the subject on a weekly basis
throughout the study. All visits were assessed to determine potential
differences/fluctuations during the treatment cycle (e.g., peak effect,
waning).
Safety. Subjects were asked to report all adverse events (AEs) that
occurred in the observation period after their first injection.
Statistical methodology
Sample size determination. Owing to the prospective, observational
design of this study, no formal sample size calculation was utilized.
Subject enrollment for both blepharospasm and CD was unrestricted
up to a total 1,200 subjects from up to 120 sites. The initial data-cut for
the preliminary analysis included a total of 258 subjects with
blepharospasm. Only subjects who had confirmed 4-week post-
injection data for the JRS were included in the analysis. In the event
of missing data, percentages were computed based on non-missing
data, whenever applicable.
Statistical analysis. Subject demographic, baseline disease character-
istics, injection patterns, guidance techniques, efficacy assessments
(including global impression measures, JRS, QoL, and measures of
work productivity), and safety assessments per injection session were
summarized descriptively. Categorical variables were summarized as
counts and percentages using the number of observations available as
the denominator for calculation of percentages. Continuous variables
were summarized using mean and standard deviation (SD), median,
and range. Comparisons were made with paired t tests. No imputation
for missing data was performed.
Results
Subjects
Data are reported from an interim analysis of the first 170 subjects
(131 females) who had a diagnosis of blepharospasm, enrolled from 29
centers across the USA and who completed 4 weeks of follow-up
assessments. The majority were female (77.1%) and white (91.8%).
At the time of the first visit, the mean estimated duration of disease
for the enrolled subjects was 10.9 years; mean age at disease onset was
53.9 years; and mean age at enrollment was 63.7 years. The majority
of subjects (59.2%) were employed at the time of symptom onset but
only 31.7% were employed at the time of enrollment in the study.
The majority of subjects (96.5%) had previously received treatment
with botulinum toxin, e.g., XeominH (incobotulinumtoxinA), BotoxH
(onabotulinumtoxinA), MyoblocH (rimabotulinumtoxinB), or DysportH
(abobotulinumtoxinA). Only 3.5% of participants were botulinum
toxin-naı¨ve subjects diagnosed with blepharospasm. Most subjects
(74.4%) reported a near complete/full response while 20.6% subjects
reported only a partial response to previous botulinum toxin
treatments. The remaining 5% rated their treatment as unknown.
The baseline demographics and disease characteristics are listed in
Table 1.
Dosing
In almost all cases, the orbicularis oculi muscles were injected. In
69.4% of cases, the corrugator supercilii muscles were also injected,
but only 45.3% of subjects received injections also in the procerus
muscles. The mean total dose (both eyes) per treatment for
blepharospasm was 71.5 U for the first injection in this study. The
most frequent dilution scheme was 2 mL of normal saline per 100 U
incobotulinumtoxinA; however, it ranged from 1 mL to 10 mL. Total
dose, incobotulinumtoxinA dilution, muscles injected, and dosing per
muscle are summarized in Table 2.
Clinical global impression scale-severity subscale
Investigators rated the subject’s illness using the CGI-S at baseline
(Table 3). The investigator rating at baseline shows the majority
(68.1%) of subjects were moderately to severely ill (moderately: 42.0%,
markedly: 17.2%, severely: 8.9%) and investigators rated 7.1% of the
subjects as normal. Subjects rated as ‘‘normal’’ had symptoms rated
within the normal range of the CGI-S scale. They were still included in
the study and treated, as the investigators believed they would benefit
from incobotulinumtoxinA treatment.
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Table 1. Subject Demographics and Disease Characteristics
Characteristic Blepharospasm N5170






Age at enrollment (years), mean (SD) 63.7 (11.4)
Age at onset (years), mean (SD) n5169 53.9 (12.6)
Estimated duration of disease (years), mean (SD) n5169 10.9 (8.3)
Age at first botulinum toxin treatment prior to enrollment on this study (years),
mean (SD)
n5157 58.7 (11.1)
Time since most recent botulinum toxin injection (months), mean (SD) n5163 4.3 (9.7)
Subjects with previous botulinum toxin therapy, n (%) 164 (96.5)
Previous botulinum toxin treatments2
AbobotulinumtoxinA, n (%) 4 (2.4)
Mean number of treatments (SD) n54 2.3 (1.3)
IncobotulinumtoxinA, n (%) 43 (25.3)
Mean number of treatments (SD) n543 1.6 (1.1)
OnabotulinumtoxinA, n (%) 162 (95.3)
Mean number of treatments (SD) n5152 21.8 (19.1)
RimabotulinumtoxinB, n (%) 6 (3.5)
Mean number of treatments (SD) n56 10.7 (20.8)
Effect of previous botulinum toxin treatment
None 1 (0.6)
Partial 35 (20.6)
Near complete/full 127 (74.7)
Unknown 7 (4.1)
Previous botulinum toxin duration (days), mean (SD) n5157 79.0 (31.6)
Baseline employment
Employed at time of onset N5169
Yes 100 (59.2)
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Patient global impression scale-severity and -improvement
subscales
Subjects used the PGI-S to rate their illness at baseline and 4 weeks
after injection (Table 3). At baseline, 20.6% of subjects rated themselves
as normal and 47.2% rated themselves as moderately, markedly,
severely, or extremely ill. The mean subject rating of disease severity was
less severe than the mean investigator rating. The correlation analysis
showed that the subject and physician ratings were significantly different
(correlation coefficient5 0.33959; p,0.0001). At 4 weeks after injection,
51% of subjects reported ‘‘much’’ or ‘‘very much’’ improvement.
Jankovic rating scale
Subjects rated their blepharospasm symptoms using the JRS. At
baseline, the mean (SD) severity, frequency, and total scores were 2.5
Table 1. Continued
Characteristic Blepharospasm N5170
If employed at onset, was employment status affected
Different job with less responsibility 4 (4.0)
Loss of employment 11 (11.0)
No 75 (75.0)
Same job, less pay 1 (1.0)
Unknown 9 (9.0)
Receiving or seeking disability benefits? n5161
Yes 19 (11.8)
Abbreviation: SD, Standard Deviation.
1A subject may select multiple races.
2Subjects may have received more than one serotype and thus the total number of subjects per treatment sums to more than the total number of subjects.
Percentages are based on non-missing values.
Table 2. Summary of IncobotulinumtoxinA Dosing
Blepharospasm N5170
Dose at first injection visit, mean units (SD) 71.5 (50.6)
Most frequent volume (mL) of saline/100 U incobotulinumtoxinA at
1st injection visit [range]
2 (1–10)
Dosing by muscle for both eyes: total at first injection visit,1 mean units (SD)
Orbicularis oculi, n5168 26.2 (14.7)
Procerus, n577 7.1 (5.7)
Corrugator supercilii, n5118 8.5 (7.1)
Summary of muscle identification at first injection visit, n (%)




Abbreviation: SD, Standard Deviation.
1More than one muscle could have been treated.
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(1.0), 2.4 (0.94), and 4.9 (1.7), respectively. Four weeks after injection,
the mean (SD) severity, frequency, and total scores were 1.7 (1.1), 1.5
(1.2), and 3.2 (2.2), respectively. The mean (SD) change versus baseline
was –0.81 (1.15) (p,0.0001) for the JRS severity score, 20.87 (1.2)
(p,0.0001) for the JRS frequency score, and 21.68 (2.18) (p,0.0001)
for the JRS Sumscore.
Quality of life and work history
Subjects rated their QoL using the SF-12v2. There were no
differences in either the mental or physical components of QoL at
Week 4 compared with baseline. Subjects reported work issues using
the WPAI questionnaire. On a scale of 0 to 10, subjects rated health
affecting non-work activities as a mean of 3.1 (SD 2.8). In working
subjects, health affected productivity by a mean of 1.9 (SD 2.3).
Minimal changes were seen in every area measured by the WPAI
during the first 4 weeks of treatment (Table 4).
Adverse events
Only eight subjects reported an AE including AEs that were
definitely or probably related to treatment. They included entropion,
ulcerative keratitis, contusion, dry eye, and lagophthalmos. All of the
definitely or probably related AEs were mild to moderate in severity.
Complete AE details will be published in the final study report.
Discussion
XCiDaBLE was a prospective, observational study designed to
collect, evaluate, and report data on the clinical use of
incobotulinumtoxinA in the ‘‘real-world’’ therapeutic setting. One
hundred and seventy subjects who had a diagnosis of blepharospasm
were enrolled from 29 centers across the USA. Subjects received two
treatment cycles (approximately 6 months) and completed 4 weeks of
follow-up assessments, via IVRS/IWRS.
The majority of subjects with blepharospasm who entered the trial
were female, had a mean age of 63.7 years, and had experienced
symptoms of blepharospasm for nearly 11 years. While the majority of
subjects (59.2%) were employed at the time of onset of blepharospasm
symptoms, only 31.7% were employed at the time of enrollment in the
study. In occidental countries, many people retire at the age of 63
years. It will therefore be difficult to assess the effect of the treatment
on the employment status of the subjects enrolled in this study.
Almost all subjects had previously received injections of botulinum
toxin with the majority reporting a near complete/full treatment effect
(74.7%). In general, subjects rated the severity of their disease as less
severe than did the investigators. The mean dose for the first injection
in this study was 71.5 U. These values are in line with reported doses
applied during clinical trials, ranging from 26.8 to 73 U per eye and a
mean of 66.9 U for both eyes being reported in the US pivotal trial.5–7,11
All the studies conducted using onabotulinumtoxinA as an active
comparator to incobotulinumtoxinA have utilized a 11 dosing ratio.
These studies showed incobotulinumtoxinA was non-inferior in terms of
efficacy and similar in terms of safety to onabotulinumtoxinA, and the
effects of incobotulinumtoxinA were comparable to onabotulinumtoxinA
using this dosing ratio.6,11 The orbicularis oculi and the corrugator
supercilii muscles were injected in the majority of subjects; only a minority
of subjects were injected in the procerus. While most investigators diluted
100 U of incobotulinumtoxinA with 2 mL of normal saline, the dilution
Table 3. Global Impressions (Investigator and Patient)
Blepharospasm, n (%)
Severity Improvement
Category Baseline Baseline Category 4 Weeks
(1st Injection Visit) (1st Injection Visit) Post 1st Injection
Investigator Severity Patient Severity Patient Improvement
N5169 N5165 N5159
Not assessed 0 2 (1.2) Not assessed 5 (3.1)
Normal (1) 12 (7.1) 34 (20.6) Very much improved (1) 24 (15.1)
Borderline (2) 10 (5.9) 18 (10.9) Much improved (2) 57 (35.9)
Mildly (3) 32 (18.9) 33 (20.0) Minimally improved (3) 43 (27.0)
Moderately (4) 71 (42.0) 40 (24.2) No change (4) 17 (10.7)
Markedly (5) 29 (17.2) 23 (13.9) Minimally worse (5) 5 (3.1)
Severely (6) 15 (8.9) 12 (7.3) Much worse (6) 7 (4.4)
Extremely (7) 0 3 (1.8) Very much worse (7) 1 (0.6)
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range was wide (from 1 mL to 10 mL). The recommended dose for
blepharospasm is 2.5–5.0 U/injection site.16
In this large, prospective, open-label trial, treatment with
incobotulinumtoxinA demonstrated effectiveness 4 weeks after injec-
tion as measured by patient-reported outcomes (including PGI-S and
JRS). Compared with baseline, the magnitude of improvement at 4
weeks on the JRS Sumscore was a mean of 21.7 (severity mean
change was 20.8 and frequency mean change was 20.9) in this
observational study (p,0.0001). This magnitude is significant and
similar to previously reported blinded trials.5,6 IncobotulinumtoxinA
was studied in one placebo-controlled trial (N5109 with 75 being
treated with incobotulinumtoxinA) and one active-comparator trial
(N5256 with 129 being treated with incobotulinumtoxinA).5,10
Additionally, a pilot active-comparator study has been conducted
(N564 with 31 being treated with incobotulinumtoxinA) along with a
large, long-term, repeated-dose study (N5102, all treated with up to
five treatment cycles of incobotulinumtoxinA).6,7 The magnitudes of
improvements in the Jankovic et al. placebo-controlled study at Week
3 (JRS Sumscore adjusted mean change 21.8, severity 20.9, and
frequency 20.9) and Week 6 (JRS Sumscore adjusted mean change
21.3, severity 20.8, and frequency 20.6) after injection and in the
Wabbels et al.6 active-comparator controlled study at Week 4 post
injection (JRS Sumscore mean change 21.5) are thus comparable to
that observed in our study.5,6 This also underscores another
observation that the patient-rated JRS (performed by IVRS in this
observational study) and investigator-rated JRS (performed in the
blinded trials) may be comparable and therefore of value, and thus
should be considered in future studies on blepharospasm.
Interestingly, despite meaningful improvement in specific and global
disease severity measures, at 4 weeks after injection, there were no
improvements in either QoL, as measured by the SF12v2, or in work
productivity, as measured by the WPAI questionnaire. This is likely
related to multiple factors including previous injections with toxin, and
the short—4 weeks—duration of the follow-up period in this report.
Also, the broad inclusion criteria, particularly related to employment
and working type and conditions, in the study could have led to the
lack of QoL improvement (e.g., a job that does not entail a lot of
reading or strenuous visual activity might be less likely to improve the
score of subjects most severely affected). It will be interesting to see if
there are improvements in QoL with consistent individualized
injections over a longer period.
There are limitations to this study. First, the study was an interim
report of a much larger cohort (688 subjects, 319 subjects with
blepharospasm). The sample size of this interim report on the
blepharospasm subjects was small (170 subjects), which may or may
not be indicative of the final study and limits the generalization of
the results to the total population of patients treated with incobo-
tulinumtoxinA for blepharospasm. Second, subjects were assessed
using an IVRS/IWRS. Subjects’ responses assessed by such methods
were not or could not be checked by a treating clinician or by objective
assessments.
Table 4. Summary of Work Productivity and Activity Impact Questionnaire



































Baseline (N5167) 53 (31.7) n5165 3.1 (2.8) n552 34.2 (17.0) n552 1.2 (5.7) n552 5.2 (11.0) n552 1.9 (2.3)
Week 1 (N5158) 47 (29.7) n5150 2.9 (2.9) n547 33.2 (19.5) n547 1.4 (6.3) n547 5.3 (14.2) n543 1.6 (1.7)
Week 2 (N5154) 47 (30.5) n5146 3.1 (3.0) n546 26.6 (17.1) n546 5.2 (19.4) n546 4.3 (10.8) n538 1.5 (2.1)
Week 3 (N5154) 46 (29.9) n5148 2.6 (2.7) n546 30.3 (19.6) n546 1.9 (7.8) n546 4.6 (10.1) n540 1.5 (2.1)
Week 4 (N5170) 49 (28.8) n5159 2.8 (2.8) n549 28.7 (19.2) n549 1.1 (5.9) n549 3.5 (8.9) n541 1.6 (2.0)
Abbreviation: SD, Standard Deviation.
The productivity and daily activities questions are based on a 10-point scale where 05health problems had no effect on daily activity and 105health problems
completely prevented productivity/activities. Percentages are based on non-missing values.
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IncobotulinumtoxinA has previously been shown in large trials to be
a safe and effective treatment for blepharospasm.5,7,11 In XCiDaBLE,
no new or unexpected safety issues have been uncovered.
IncobotulinumtoxinA was well tolerated in subjects with blephar-
ospasm. There were very few AEs reported; fewer safety issues were
reported as AEs in the present study compared with other studies,
which is not surprising given the ‘‘naturalistic’’ setting of this study.
Additionally, both the Jankovic and Roggenka¨mper studies involved
direct questioning regarding specific AEs that the FDA were interested
in, which led to a higher reported rate than self-reporting.5,11
Prospective, open-label studies, such as XCiDaBLE, can be useful
for physicians to understand ‘‘real-world’’ use of botulinum toxins and
how it compares to fixed, blinded trials. However, there are limitations
to this type of study. This study lacks a placebo control and therefore
all subjects and investigators knew the subjects were receiving active
treatment and would have an expectation of improvement. An
additional limitation of this study is that all of the assessments were
completed by the subject via IVRS/IWRS (which has not been
validated in subjects with blepharospasm). While this allows for more
assessments over the treatment period, the onus is on the subject to
actually complete the assessments. Nonetheless, this ongoing study is
providing information on the disease characteristics of subjects with
blepharospasm treated with botulinum toxin. It is worth noting that:
the illness severity ratings of clinicians were worse than the subjects’
rating of their own illness; the range of dilution with normal saline was
large; and the patient-rated JRS improvement in this open-label study
was comparable to the investigator-rated JRS improvement observed
in previously blinded studies. Indeed, these interim data confirm that
the magnitude of effect seen in this naturalistic study is similar to that
seen in previous blinded studies with incobotulinumtoxinA.
This study reports that incobotulinumtoxinA remained well
tolerated with comparable magnitude of effect over a broad spectrum
of dose and dilution when used in a less selective and wider range of
subjects with blepharospasm than the more selective inclusion of
subjects in blinded trials employing uniform dilution and stricter
dosing guidelines. Patient-rated JRS should be considered as an
outcome measure in future observational studies and clinical trials for
blepharospasm. Caution should be used in studies where only the PGI-
S or CGI-S are utilized, as correlation between these two scales may
not be optimal. Despite showing significant benefits in specific and
global measures of disease severity, improvement in QoL was not
captured in the short-term period of this interim report.
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